Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
Boehringer Ingelheim
Dow
Argus Health
QuintilesIMS
Medtronic
Queensland Health
McKinsey

Generated: August 21, 2018

DrugPatentWatch Database Preview

KETEK Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Ketek patents expire, and what generic alternatives are available?

Ketek is a drug marketed by Sanofi Aventis Us and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-three patent family members in thirty-nine countries.

The generic ingredient in KETEK is telithromycin. Additional details are available on the telithromycin profile page.

Summary for KETEK
International Patents:63
US Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: 55
Patent Applications: 2,459
Formulation / Manufacturing:see details
DailyMed Link:KETEK at DailyMed
Drug patent expirations by year for KETEK
Synonyms for KETEK
(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]-12,15-dioxa-17-azabicyclo[12.
(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptade
(1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptade
(1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptade
(1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadeca
(1R,2R,4R,6S,7R,8R,10R,13S,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]-12,15-dioxa-17-azabicyclo[12.
(1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]-12,15-dioxa-17-azabicyclo[12.
(1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptade
(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-(4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)butyl)-10-((3,4,6-trideoxy-3-(dimethylamino)-b-d-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecin
(3R,5S,6S,7R,8S,11S,12R,13S,14R,15S)-12- [(4-O-ACETYL-2,6-DIDEOXY-3-O-METHYL-ALPHA-L-ARABINO-HEXOPYRANOSYL) OXY] -14-{[2-O-ACETYL-3,4,6-TRIDEOXY-3-(DIMETHYLAMINO) BETA-D-XYLO-HEXOPYRANOSYL]OXY} -5,7,8,11,13,15-HEXAMETHYL-4,10
11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
114T484
173838-31-8
191114-48-4
AB0105876
AB2000711
AC-1692
AC1L2K8V
AC1MHE79
AC1NUZ37
AK481284
AKOS015896612
AKOS015961934
AKOS016339661
AKOS025394487
AN-14683
BC208806
BDBM50378137
BSPBio_002692
C12009
C43H65N5O10
CAS-191114-48-4
CCG-101183
CHEBI:29688
CHEMBL1136
CPD000469222
CS-2812
CTK8E7317
D01078
D09HNR
DB00976
DSSTox_CID_26455
DSSTox_GSID_46455
DSSTox_RID_81629
DTXSID3046455
Erythromycin, 3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-
Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-
HMR 3647
HMR-3647
HMR3647
HMR3647;RU66647
HMS2052B11
HSDB 7359
HY-A0062
I06-2338
Ketek (TN)
KI8H7H19WL
KS-00001F5X
Levviax
LS-182988
MFCD00943561
MLS001424285
MolPort-006-823-578
MolPort-009-680-776
MolPort-023-220-177
MRF-0000457
NC00433
NCGC00164575-01
NCGC00178527-01
NSC-758940
NSC758940
Pharmakon1600-01505265
RT-015897
RU 66647
RU-66647
RU66647
SAM001246805
SCHEMBL5100
SMR000469222
T-1460
Telithromycin
Telithromycin (JAN/USAN/INN)
Telithromycin (Ketek)
Telithromycin [USAN:BAN:INN]
Telithromycin [USAN:INN:BAN]
Telithromycin, Antibiotic for Culture Media Use Only
Tox21_111454
Tox21_112203
UNII-KI8H7H19WL
VA11985
ZINC91302264
ZINC95617679
ZINC9574770
ZINC95803259

US Patents and Regulatory Information for KETEK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for KETEK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-001 Apr 1, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us KETEK telithromycin TABLET;ORAL 021144-002 Feb 9, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for KETEK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,100,404 Erythromycin compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for KETEK

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/001 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TELITHROMYCIN AND ADDITION SALTS THEREOF WITH PHARMACEUTICALLY ACCEPTABLE ACIDS; REGISTERED: UK EU/1/01/191/001-004 20010710
C0055 France ➤ Try a Free Trial PRODUCT NAME: TELITHROMYCINE; REGISTRATION NO/DATE: EU/1/01/191/001 20010709
2002 00001 Denmark ➤ Try a Free Trial DKCTFF , , EXPIRES:
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Express Scripts
Cipla
Chinese Patent Office
UBS
Daiichi Sankyo
Fish and Richardson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.